Amneal Pharmaceuticals is trading at $21.02, up +4.37%, alongside a broad U.S. market rebound.
- Reuters described Monday’s recovery as bargain-hunting after last week’s steep equity selloff.
- Amneal’s November 3 results beat estimates, and the company raised 2026 guidance; available reporting does not establish either as the direct cause of this session’s move.
- No new company-specific announcement explaining the November 9 move surfaced in the search.